title: Ticagrelor Versus Clopidogrel in Comatose Survivors of Out-of-Hospital Cardiac Arrest Undergoing Percutaneous Coronary Intervention and Hypothermia: A Randomized Study.
authors.affiliation: From Center for Intensive Internal Medicine (K.S., M.F., U.M., M.N.), and Department of Vascular Diseases (A.B., M.B.M.), University Medical Center, Ljubljana, Slovenia.
authors.forename: Klemen
authors.initials: K
authors.lastname: Steblovnik
authors.affiliation: From Center for Intensive Internal Medicine (K.S., M.F., U.M., M.N.), and Department of Vascular Diseases (A.B., M.B.M.), University Medical Center, Ljubljana, Slovenia.
authors.forename: Ales
authors.initials: A
authors.lastname: Blinc
authors.affiliation: From Center for Intensive Internal Medicine (K.S., M.F., U.M., M.N.), and Department of Vascular Diseases (A.B., M.B.M.), University Medical Center, Ljubljana, Slovenia.
authors.forename: Mojca Bozic
authors.initials: MB
authors.lastname: Mijovski
authors.affiliation: From Center for Intensive Internal Medicine (K.S., M.F., U.M., M.N.), and Department of Vascular Diseases (A.B., M.B.M.), University Medical Center, Ljubljana, Slovenia.
authors.forename: Misa
authors.initials: M
authors.lastname: Fister
authors.affiliation: From Center for Intensive Internal Medicine (K.S., M.F., U.M., M.N.), and Department of Vascular Diseases (A.B., M.B.M.), University Medical Center, Ljubljana, Slovenia.
authors.forename: Ursa
authors.initials: U
authors.lastname: Mikuz
authors.affiliation: From Center for Intensive Internal Medicine (K.S., M.F., U.M., M.N.), and Department of Vascular Diseases (A.B., M.B.M.), University Medical Center, Ljubljana, Slovenia. marko.noc@mf.uni-lj.si.
authors.forename: Marko
authors.initials: M
authors.lastname: Noc
mesh_terms: D065767:Activation, Metabolic; D000241:Adenosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000077144:Clopidogrel; D003128:Coma / Q000175:diagnosis / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007036:Hypothermia, Induced / Q000009:adverse effects / Q000401:mortality; D058687:Out-of-Hospital Cardiac Arrest / Q000175:diagnosis / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000401:mortality; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010979:Platelet Function Tests; D058921:Purinergic P2Y Receptor Antagonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012151:Resuscitation; D000077486:Ticagrelor; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D000077144:Clopidogrel; D000077486:Ticagrelor; D000241:Adenosine; D013988:Ticlopidine
keywords: cardiac arrest; percutaneous coronary intervention; platelet inhibitor